NCT02626481 2026-04-07
IFM2014-04
University Hospital, Lille
Phase 2 Completed
Clinical Trials
54 trialsNCT03477539 2026-03-09
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT06549634 2026-02-27
Biomarkers of AKI in Patients Receiving Daratumumab
Brigham and Women's Hospital
Completed
NCT01665794 2025-12-22
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Chicago
Phase 1/2 Completed
NCT03180736 2025-12-19
EMN14
European Myeloma Network B.V.
Phase 3 Completed
NCT05182073 2025-12-12
FT576 in Subjects With Multiple Myeloma
Fate Therapeutics
Phase 1 Completed
NCT05511428 2025-11-21
Home Based Daratumumab Administration for Patients With Multiple Myeloma
Thomas Jefferson University
Phase 4 Completed
NCT01592370 2025-10-22
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01415882 2025-09-05
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Mayo Clinic
Phase 2 Completed
NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT05835726 2025-08-15
DILEMMA
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Completed
NCT06055075 2025-07-14
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1/2 Completed
NCT01946477 2025-06-06
POM MM 014
Celgene
Phase 2 Completed
NCT03012880 2025-06-04
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT03490344 2025-05-25
Short Course Daratumumab in Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03158688 2025-05-09
CANDOR
Amgen
Phase 3 Completed
NCT02076009 2025-05-01
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03412565 2025-04-29
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
Phase 2 Completed
NCT02316106 2025-04-27
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT05243342 2025-02-17
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Completed
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT02874742 2025-02-04
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT03357952 2025-02-04
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 2/3 Completed
NCT02918331 2025-02-03
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT03768960 2025-02-03
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
Johnson & Johnson Private Limited
Phase 4 Completed
NCT05284591 2024-10-01
MYLENE
iOMEDICO AG
Completed
NCT03439293 2024-07-03
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda
Phase 2 Completed
NCT05679258 2024-06-28
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects
Shanghai Henlius Biotech
Phase 1 Completed
NCT03234972 2024-05-29
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03217812 2024-04-25
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC
Phase 3 Completed
NCT05306587 2024-04-03
Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.
Odense University Hospital
Completed
NCT03450057 2024-03-29
DARE
Hellenic Society of Hematology
Phase 2 Completed
NCT03311828 2024-03-12
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT04121260 2023-12-08
A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT03224507 2023-11-24
MASTER
University of Alabama at Birmingham
Phase 2 Completed
NCT03215524 2023-08-04
DCDP
Canadian Myeloma Research Group
Phase 2 Completed
NCT04136756 2023-06-15
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Nektar Therapeutics
Phase 1 Completed
NCT02977494 2022-05-31
GMMG-DANTE
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Completed
NCT04280328 2022-03-11
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
Corvus Pharmaceuticals, Inc.
Phase 1 Completed
NCT03697629 2022-02-15
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Canadian Myeloma Research Group
Phase 2 Completed
NCT04065789 2022-01-27
KyDaR
Tel-Aviv Sourasky Medical Center
Phase 2 Completed
NCT02951819 2021-10-08
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Janssen Scientific Affairs, LLC
Phase 2 Completed
NCT02431208 2021-04-02
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hoffmann-La Roche
Phase 1 Completed
NCT02852837 2020-11-16
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
Janssen Research & Development, LLC
Phase 1 Completed
NCT03068351 2020-02-07
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hoffmann-La Roche
Phase 1 Completed
NCT02944565 2019-09-09
Daratumumab in Treating Patients With Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02497378 2019-03-07
A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT03000452 2018-10-16
FUSION-MM-005
Celgene
Phase 2 Completed